Ophiomics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
4
Ophiomics General Information
Description
Developer of a medical diagnostic product designed to integrate bioinformatics and genomics to detect liver cancer at an early stage. The company's products include biomarker-based diagnostic devices to identify hepatocellular carcinoma by integrating molecular signatures with clinical parameters in a predictive algorithm, enabling healthcare providers to detect lung cancer and improve prognosis in patients.
Contact Information
Website
www.ophiomics.comCorporate Office
- Pólo Tecnológico de Lisboa
- Rua António Champalimaud, Lote 1 (sala 14)
- Lisbon, 1600-513
- Portugal
Corporate Office
- Pólo Tecnológico de Lisboa
- Rua António Champalimaud, Lote 1 (sala 14)
- Lisbon, 1600-513
- Portugal
Ophiomics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Accelerator/Incubator | 14-Dec-2025 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 5. Later Stage VC (Series A) | 08-Dec-2022 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 28-Apr-2021 | Completed | Generating Revenue | |||
| 3. Grant | 28-Sep-2020 | Completed | Generating Revenue | |||
| 2. Grant | 09-Oct-2019 | $833K | Completed | Generating Revenue | ||
| 1. University Spin-Out | 01-Jan-2015 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Ophiomics Patents
Ophiomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4341441-A1 | Dna methylation biomarkers for hepatocellular carcinoma | Pending | 21-May-2021 | ||
| US-20240229158-A1 | Dna methylation biomarkers for hepatocellular carcinoma | Pending | 21-May-2021 | ||
| WO-2022243566-A1 | Dna methylation biomarkers for hepatocellular carcinoma | Inactive | 21-May-2021 | C12Q1/6886 |
Ophiomics Signals
Ophiomics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Saudi Biotechnology Accelerator | Accelerator/Incubator | |||
| BlueCrow Capital | Venture Capital | Minority | ||
| Everis Awards | Not-For-Profit Venture Capital | |||
| Universidade NOVA de Lisboa | University |
Ophiomics FAQs
-
When was Ophiomics founded?
Ophiomics was founded in 2015.
-
Where is Ophiomics headquartered?
Ophiomics is headquartered in Lisbon, Portugal.
-
What is the size of Ophiomics?
Ophiomics has 14 total employees.
-
What industry is Ophiomics in?
Ophiomics’s primary industry is Diagnostic Equipment.
-
Is Ophiomics a private or public company?
Ophiomics is a Private company.
-
What is Ophiomics’s current revenue?
The current revenue for Ophiomics is .
-
How much funding has Ophiomics raised over time?
Ophiomics has raised $1.19M.
-
Who are Ophiomics’s investors?
Saudi Biotechnology Accelerator, BlueCrow Capital, Everis Awards, and Universidade NOVA de Lisboa have invested in Ophiomics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process